These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Patil V; Gada K; Panwar R; Varvarigou A; Majewski S; Weisenberger A; Ferris C; Tekabe Y; Khaw BA Eur J Nucl Med Mol Imaging; 2012 May; 39(5):824-39. PubMed ID: 22302089 [TBL] [Abstract][Full Text] [Related]
9. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715 [TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077 [TBL] [Abstract][Full Text] [Related]
11. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. Le Doussal JM; Chetanneau A; Gruaz-Guyon A; Martin M; Gautherot E; Lehur PA; Chatal JF; Delaage M; Barbet J J Nucl Med; 1993 Oct; 34(10):1662-71. PubMed ID: 8410279 [TBL] [Abstract][Full Text] [Related]
12. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150 [TBL] [Abstract][Full Text] [Related]
13. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754 [TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373 [TBL] [Abstract][Full Text] [Related]
16. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586 [TBL] [Abstract][Full Text] [Related]
17. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333 [TBL] [Abstract][Full Text] [Related]
18. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. Lamki LM; Patt YZ; Rosenblum MG; Shanken LJ; Thompson LB; Schweighardt SA; Frincke JM; Murray JL Radiology; 1990 Jan; 174(1):147-51. PubMed ID: 2294542 [TBL] [Abstract][Full Text] [Related]
19. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353 [TBL] [Abstract][Full Text] [Related]
20. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]